2025
Surgical Management of Breast Cancer Liver Metastasis
Rahnemai-Azar A, Selby L, Lustberg M, Pawlik T. Surgical Management of Breast Cancer Liver Metastasis. Hematology/Oncology Clinics Of North America 2025, 39: 25-35. PMID: 39510675, DOI: 10.1016/j.hoc.2024.08.012.Peer-Reviewed Original ResearchConceptsBreast cancer liver metastasesSystemic chemotherapyHepatic resectionAblation therapyIsolated breast cancer liver metastasesLong-term outcomes of womenProlonged disease-free intervalLocal-regional therapyCancer liver metastasesDisease-free intervalOutcomes of womenBreast cancer metastasisLong-term outcomesRegional therapyLiver metastasesOverall survivalSurgery benefitMultidisciplinary settingCancer metastasisPatientsResectionChemotherapyMetastasisTherapySurgery
2024
Artificial Intelligence–Driven Patient Selection for Preoperative Portal Vein Embolization for Patients with Colorectal Cancer Liver Metastases
Kuhn T, Engelhardt W, Kahl V, Alkukhun A, Gross M, Iseke S, Onofrey J, Covey A, Camacho J, Kawaguchi Y, Hasegawa K, Odisio B, Vauthey J, Antoch G, Chapiro J, Madoff D. Artificial Intelligence–Driven Patient Selection for Preoperative Portal Vein Embolization for Patients with Colorectal Cancer Liver Metastases. Journal Of Vascular And Interventional Radiology 2024, 36: 477-488. PMID: 39638087, DOI: 10.1016/j.jvir.2024.11.025.Peer-Reviewed Original ResearchTotal liver volumeMetastatic colorectal cancer patientsPreoperative portal vein embolizationColorectal cancer liver metastasesPortal vein embolizationCancer liver metastasesMulticenter retrospective studyColorectal cancer patientsStudent's t-testBoard-certified radiologistsVein embolizationConsecutive patientsLiver metastasesLiver volumePatient selectionRetrospective studyCancer patientsRadiomic featuresInclusion criteriaPatientsSemi-automatic segmentationLab valuesT-testSDAUCNew insights into macrophage polarization and its prognostic role in patients with colorectal cancer liver metastasis
Khanduri I, Maki H, Verma A, Katkhuda R, Anandappa G, Pandurengan R, Zhang S, Mejia A, Tong Z, Solis Soto L, Jadhav A, Wistuba I, Menter D, Kopetz S, Parra E, Vauthey J, Maru D. New insights into macrophage polarization and its prognostic role in patients with colorectal cancer liver metastasis. BJC Reports 2024, 2: 37. PMID: 39516662, PMCID: PMC11523988, DOI: 10.1038/s44276-024-00056-8.Peer-Reviewed Original ResearchColorectal cancer liver metastasesRecurrence-free survivalCancer liver metastasesTumor-associated macrophagesT cell subtypesPreoperative chemotherapyLiver metastasesT cellsColorectal cancer liver metastases patientsM2 macrophagesAssociated with shorter recurrence-free survivalShorter recurrence-free survivalPredictor of favorable prognosisRegulatory T cellsMacrophage polarizationCytotoxic T cellsHelper T cellsDensity of M2 macrophagesCause of mortalityFavorable prognosisPrognostic roleM2 macrophage polarizationTumor biologyTumor samplesColorectal cancer
2023
Multi-omic analysis reveals metabolic pathways that characterize right-sided colon cancer liver metastasis
Morris M, Jain A, Sun B, Kurbatov V, Muca E, Zeng Z, Jin Y, Roper J, Lu J, Paty P, Johnson C, Khan S. Multi-omic analysis reveals metabolic pathways that characterize right-sided colon cancer liver metastasis. Cancer Letters 2023, 574: 216384. PMID: 37716465, PMCID: PMC10620771, DOI: 10.1016/j.canlet.2023.216384.Peer-Reviewed Original ResearchConceptsLiver metastasesColon cancer liver metastasisCancer liver metastasesSided colon cancerSubset of patientsGrowth factor betaMulti-omics analysisFatty acid oxidationMetastatic diseaseInferior survivalClinical differencesClinical behaviorUntargeted metabolomics analysisTumor behaviorColon cancerBile acidsTumor cell metabolismFactor betaPatientsMetastasisPI3K-AktReactive oxygen speciesMEK-ERKLiquid chromatography-mass spectrometryRCC
2022
Dragon 1 Protocol Manuscript: Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy
Korenblik R, Olij B, Aldrighetti LA, Hilal MA, Ahle M, Arslan B, van Baardewijk LJ, Baclija I, Bent C, Bertrand CL, Björnsson B, de Boer MT, de Boer SW, Bokkers RPH, Rinkes IHMB, Breitenstein S, Bruijnen RCG, Bruners P, Büchler MW, Camacho JC, Cappelli A, Carling U, Chan BKY, Chang DH, choi J, Font JC, Crawford M, Croagh D, Cugat E, Davis R, De Boo DW, De Cobelli F, De Wispelaere JF, van Delden OM, Delle M, Detry O, Díaz-Nieto R, Dili A, Erdmann JI, Fisher O, Fondevila C, Fretland Å, Borobia FG, Gelabert A, Gérard L, Giuliante F, Gobardhan PD, Gómez F, Grünberger T, Grünhagen DJ, Guitart J, Hagendoorn J, Heil J, Heise D, Herrero E, Hess GF, Hoffmann MH, Iezzi R, Imani F, Nguyen J, Jovine E, Kalff JC, Kazemier G, Kingham TP, Kleeff J, Kollmar O, Leclercq WKG, Ben SL, Lucidi V, MacDonald A, Madoff DC, Manekeller S, Martel G, Mehrabi A, Mehrzad H, Meijerink MR, Menon K, Metrakos P, Meyer C, Moelker A, Modi S, Montanari N, Navines J, Neumann UP, Peddu P, Primrose JN, Qu X, Raptis D, Ratti F, Ridouani F, Rogan C, Ronellenfitsch U, Ryan S, Sallemi C, Moragues JS, Sandström P, Sarriá L, Schnitzbauer A, Serenari M, Serrablo A, Smits MLJ, Sparrelid E, Spüntrup E, Stavrou GA, Sutcliffe RP, Tancredi I, Tasse JC, Udupa V, Valenti D, Fundora Y, Vogl TJ, Wang X, White SA, Wohlgemuth WA, Yu D, Zijlstra IAJ, Binkert CA, Bemelmans MHA, van der Leij C, Schadde E, van Dam RM. Dragon 1 Protocol Manuscript: Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy. CardioVascular And Interventional Radiology 2022, 45: 1391-1398. PMID: 35790566, PMCID: PMC9458562, DOI: 10.1007/s00270-022-03176-1.Peer-Reviewed Original ResearchConceptsFuture liver remnant hypertrophyHepatic vein embolizationMulticenter prospective single-arm trialResectable colorectal cancer liver metastasesColorectal cancer liver metastasesProspective single-arm trialFeasibility of resectionCancer liver metastasesDisease-free survivalSingle-arm trialSmall FLRPrimary endpointSecondary endpointsFLR hypertrophyLiver metastasesOverall survivalProspective trialVein embolizationLiver functionSafety profileArm trialLiver volumeWeek 1Week 3Study centers
2021
Identifying enhancement-based staging markers on baseline MRI in patients with colorectal cancer liver metastases undergoing intra-arterial tumor therapy
Ghani MA, Fereydooni A, Chen E, Letzen B, Laage-Gaupp F, Nezami N, Deng Y, Gan G, Thakur V, Lin M, Papademetris X, Schernthaner RE, Huber S, Chapiro J, Hong K, Georgiades C. Identifying enhancement-based staging markers on baseline MRI in patients with colorectal cancer liver metastases undergoing intra-arterial tumor therapy. European Radiology 2021, 31: 8858-8867. PMID: 34061209, PMCID: PMC8848338, DOI: 10.1007/s00330-021-08058-7.Peer-Reviewed Original ResearchConceptsColorectal cancer liver metastasesCancer liver metastasesTotal tumor volumeIntra-arterial therapyTotal liver volumeLiver metastasesTumor volumeTumor burdenTumor diameterPatient survivalBaseline MRILiver volumeMultivariable Cox proportional hazards modelsKaplan-Meier survival curvesWhole liverCox proportional hazards modelKaplan-Meier methodPrognostic staging systemSurvival of patientsColorectal cancer metastasisMethodsThis retrospective studyPre-treatment MRIProportional hazards modelAppropriate cutoff valueHR 1.7
2020
Surgical Management of Breast Cancer Liver Metastasis
Rahnemai-Azar AA, Selby LV, Lustberg MB, Pawlik TM. Surgical Management of Breast Cancer Liver Metastasis. Surgical Oncology Clinics Of North America 2020, 30: 27-37. PMID: 33220807, DOI: 10.1016/j.soc.2020.09.003.Peer-Reviewed Original ResearchConceptsBreast cancer liver metastasesCancer liver metastasesSystemic chemotherapyHepatic resectionLiver metastasesAblative therapyProlonged disease-free intervalDisease-free intervalBetter overall survivalLong-term outcomesLocal-regional therapyEffective systemic chemotherapyBreast cancer metastasisLimited diseaseOverall survivalRegional therapySurgical managementSurgery benefitMultidisciplinary settingPatientsCancer metastasisMetastasisTherapyResectionChemotherapy
2018
Irinotecan-Eluting 75–150-μm Embolics Lobar Chemoembolization in Patients with Colorectal Cancer Liver Metastases: A Prospective Single-Center Phase I Study
Fereydooni A, Letzen B, Ghani MA, Miszczuk MA, Huber S, Chapiro J, Schlachter T, Geschwind JF, Georgiades C. Irinotecan-Eluting 75–150-μm Embolics Lobar Chemoembolization in Patients with Colorectal Cancer Liver Metastases: A Prospective Single-Center Phase I Study. Journal Of Vascular And Interventional Radiology 2018, 29: 1646-1653.e5. PMID: 30337148, DOI: 10.1016/j.jvir.2018.08.010.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsBiomarkers, TumorChemoembolization, TherapeuticColorectal NeoplasmsConnecticutDrug CarriersFeasibility StudiesFemaleHumansIrinotecanLiver NeoplasmsMaleMicrospheresMiddle AgedPalliative CareProspective StudiesTime FactorsTomography, X-Ray ComputedTreatment OutcomeVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth Factor Receptor-2ConceptsVascular endothelial growth factor receptor 1Transarterial chemoembolizationAdverse eventsMetastatic diseaseObjective responseColorectal cancer liver metastasesLiver-dominant metastatic diseaseMetastatic colorectal cancer refractorySingle-center phase IColorectal cancer refractoryLines of chemotherapyMedian overall survivalPrimary end pointCancer liver metastasesResponse Evaluation CriteriaOnly grade 3Drug-eluting embolicsImaging-based criteriaGrowth factor receptor 1Factor receptor 1World Health OrganizationCancer refractoryAbdominal painSystemic chemotherapyLiver metastases
2017
miR-146a targets c-met and abolishes colorectal cancer liver metastasis
Bleau AM, Redrado M, Nistal-Villan E, Villalba M, Exposito F, Redin E, de Aberasturi AL, Larzabal L, Freire J, Gomez-Roman J, Calvo A. miR-146a targets c-met and abolishes colorectal cancer liver metastasis. Cancer Letters 2017, 414: 257-267. PMID: 29133238, DOI: 10.1016/j.canlet.2017.11.008.Peer-Reviewed Original ResearchConceptsCRC liver metastasesLiver metastasesMiR-146aColorectal cancerPrimary tumorColorectal cancer liver metastasesLiver metastatic variantsMC38 adenocarcinoma cellsCancer liver metastasesCRC patientsMajor complicationsTreatment optionsDisease progressionMouse modelMetastasisMetastatic clonesSerial transplantationAdenocarcinoma cellsGene expression arraysHigh expressionMetastatic variantsDeadliest typesNew targetsMicroRNA profilingExpression levelsPrognostic signatures of oligometastasis in colorectal cancer liver metastasis.
Khan S, Paty P, Zeng Z, Lu J. Prognostic signatures of oligometastasis in colorectal cancer liver metastasis. Journal Of Clinical Oncology 2017, 35: 3588-3588. DOI: 10.1200/jco.2017.35.15_suppl.3588.Peer-Reviewed Original ResearchColorectal cancer liver metastasesCancer liver metastasesHox gene familyLiver metastasesGene familyLonger recurrence-free survivalUnique molecular subtypePrimary colorectal cancerRecurrence-free survivalSelection of patientsRisk of recurrenceUseful prognostic informationFrozen tumor tissueCRCLM patientsOligometastatic phenotypeMetastasis resectionFree survivalLimited metastasesLiver resectionOverall survivalClinical outcomesWidespread metastasesFurther mechanistic studiesColorectal cancerHOX family members
2016
Colorectal Cancer Liver Metastases: Biopsy of the Ablation Zone and Margins Can be Used to Predict Oncologic Outcome
Sotirchos V, Petrovic L, Gönen M, Klimstra D, Do R, Petre E, Garcia A, Barlas A, Erinjeri J, Brown K, Covey A, Alago W, Brody L, DeMatteo R, Kemeny N, Solomon S, Manova-Todorova K, Sofocleous C. Colorectal Cancer Liver Metastases: Biopsy of the Ablation Zone and Margins Can be Used to Predict Oncologic Outcome. Radiology 2016, 280: 949-59. PMID: 27010254, PMCID: PMC5006720, DOI: 10.1148/radiol.2016151005.Peer-Reviewed Original ResearchConceptsColorectal cancer liver metastasesLocal tumor progressionMargin sizeOncological outcomesBiopsy resultsTumor sizeRF ablationTumor cellsCumulative incidence of local tumor progressionFollow-upIncidence of local tumor progressionPredictor of local tumor progressionPredicting local tumor progressionMaterial-enhanced CT imagesProspective institutional review board-approvedMean tumor sizeMinimal ablative marginPositive biopsy resultsInstitutional review board approvalCancer liver metastasesComplete tumor ablationHIPAA-compliant studyAblation zonePredicting oncological outcomesReview board approval
2013
Evaluation of YO-PRO-1 as an early marker of apoptosis following radiofrequency ablation of colon cancer liver metastases
Fujisawa S, Romin Y, Barlas A, Petrovic L, Turkekul M, Fan N, Xu K, Garcia A, Monette S, Klimstra D, Erinjeri J, Solomon S, Manova-Todorova K, Sofocleous C. Evaluation of YO-PRO-1 as an early marker of apoptosis following radiofrequency ablation of colon cancer liver metastases. Cytotechnology 2013, 66: 259-273. PMID: 24065619, PMCID: PMC3918265, DOI: 10.1007/s10616-013-9565-3.Peer-Reviewed Original ResearchColorectal-cancer liver metastasesYO-PRO-1Liver metastasesColon cancer liver metastasisLiver tissuePropidium iodineCancer liver metastasesMouse liverMarkers of cell deathMinimally invasive treatmentMouse liver parenchymaSurrounding liver tissueMarkers of apoptosisSurgical resectionPlasma membrane injuryRadiofrequency ablationDynamic CTPI signalingNonsurgical patientsPathological examinationTarget tumorsInvasive treatmentPositive cellsBiopsy samplesNormal mouse liver
2012
Su1539 Safety and Outcomes Following Resection of Colorectal Cancer Liver Metastases in the Era of FOLFOX
Gur I, Wagner J, Sheppard B, Orloff S, Vaccaro G, Lopez C, Diggs B, Billingsley K. Su1539 Safety and Outcomes Following Resection of Colorectal Cancer Liver Metastases in the Era of FOLFOX. Gastroenterology 2012, 142: s-1058. DOI: 10.1016/s0016-5085(12)64105-5.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply